Antibiotic resistance and resistance mechanisms in Campylobacter jejuni and Campylobacter coli

被引:178
作者
Alfredson, David A.
Korolik, Victoria
机构
[1] Griffith Univ, Inst Glycom, Southport, Qld 4215, Australia
[2] St John God Pathol, Geelong, Vic, Australia
关键词
Campylobacter; antibiotic; resistance; mechanisms;
D O I
10.1111/j.1574-6968.2007.00935.x
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Campylobacter jejuni and Campylobacter coli are recognized as the most common causative agents of bacterial gastroenteritis in the world and infections with these organisms occur more frequently than do infections due to Salmonella species, Shigella species, or Escherichia coli O157:H7. The incidence of human Campylobacter infections has increased markedly in both developed and developing countries worldwide and, more significantly, so has the rapid emergence of antibiotic-resistant Campylobacter strains, with evidence suggesting that the use of antibiotics, in particular the fluoroquinolones, as growth promoters in food animals and the veterinary industry is accelerating this trend. In this minireview, the patterns of emerging resistance to the antimicrobial agents useful in treatment of the disease are presented and the mechanisms of resistance to these drugs in Campylobacter spp are discussed.
引用
收藏
页码:123 / 132
页数:10
相关论文
共 101 条
[1]  
Aarestrup FM, 2001, VET RES, V32, P311, DOI 10.1051/vetres:2001127
[2]   Effect of abolishment of the use of antimicrobial agents for growth promotion on occurrence of antimicrobial resistance in fecal enterococci from food animals in Denmark [J].
Aarestrup, FM ;
Seyfarth, AM ;
Emborg, HD ;
Pedersen, K ;
Hendriksen, RS ;
Bager, F .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (07) :2054-2059
[3]   DEVELOPMENT OF RESISTANCE TO QUINOLONES IN 5 PATIENTS WITH CAMPYLOBACTERIOSIS TREATED WITH NORFLOXACIN OR CIPROFLOXACIN [J].
ADLERMOSCA, H ;
LUTHYHOTTENSTEIN, J ;
LUCCHINI, GM ;
BURNENS, A ;
ALTWEGG, M .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1991, 10 (11) :953-956
[4]   Interaction of CmeABC and CmeDEF in conferring antimicrobial resistance and maintaining cell viability in Campylobacter jejuni [J].
Akiba, M ;
Lin, J ;
Barton, YW ;
Zhang, QJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 57 (01) :52-60
[5]   Isolation and expression of a novel molecular class D β-lactamase, OXA-61, from Campylobacter jejuni [J].
Alfredson, DA ;
Korolik, V .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (06) :2515-2518
[6]  
Allos BM, 2001, CLIN INFECT DIS, V32, P1201, DOI 10.1086/319760
[7]  
[Anonymous], 2000, Campylobacter
[8]  
[Anonymous], 1985, HDB EXPT PHARM
[9]   Single or double mutational alterations of GyrA associated with fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli [J].
Bachoual, R ;
Ouabdesselam, S ;
Mory, F ;
Lascols, C ;
Soussy, CJ ;
Tankovic, J .
MICROBIAL DRUG RESISTANCE, 2001, 7 (03) :257-261
[10]   Involvement of a plasmid in virulence of Campylobacter jejuni 81-176 [J].
Bacon, DJ ;
Alm, RA ;
Burr, DH ;
Hu, L ;
Kopecko, DJ ;
Ewing, CP ;
Trust, TJ ;
Guerry, P .
INFECTION AND IMMUNITY, 2000, 68 (08) :4384-4390